Balance Sheet
Accumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aimei Health Technology (AFJK) Cash & Equivalents (2023 - 2025)

Aimei Health Technology (AFJK) has 3 years of Cash & Equivalents data on record, last reported at $2979.0 in Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 97.12% to $2979.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2979.0, a 97.12% decrease, with the full-year FY2024 number at $28208.0, down 95.14% from a year prior.
  • Cash & Equivalents reached $2979.0 in Q3 2025 per AFJK's latest filing, down from $7345.0 in the prior quarter.
  • Over the last five years, Cash & Equivalents for AFJK hit a ceiling of $580717.0 in Q4 2023 and a floor of $2979.0 in Q3 2025.
  • A 3-year average of $184865.7 and a median of $103559.0 in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 95.14% in 2024, then crashed 98.22% in 2025.
  • Tracing AFJK's Cash & Equivalents over 3 years: stood at $580717.0 in 2023, then plummeted by 95.14% to $28208.0 in 2024, then crashed by 89.44% to $2979.0 in 2025.
  • Business Quant data shows Cash & Equivalents for AFJK at $2979.0 in Q3 2025, $7345.0 in Q1 2025, and $28208.0 in Q4 2024.